Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a do ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus ...

JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company ...

Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of ...

“We made significant progress across our pipeline over the last quarter, including completing enrollment in our Phase 3 PEAK trial in Gastrointestinal Stromal Tumor (GIST) patients, accelerating ...

Sunitinib Malate Market Sunitinib Malate Market Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "Sunitinib Malate - Global ...

The Prince and Princess of Wales made their first high-profile appearance in months at the Festival of Remembrance at the Royal Albert Hall on Saturday night. As they arrived, Prince William ...

A recent study has developed a new molecular classification for gastrointestinal stromal tumours through multi-omics analysis ...

Penn Ovarian Cancer Research Center and Basser Center for BRCA, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States ...

After the surgery, the medical team determined that the tumour was a gastrointestinal stromal tumour (GIST), a rare cancer ...